ArriVent Biopharma initiated with a Buy at JonesResearch

JonesResearch initiated coverage of ArriVent Biopharma (AVBP) with a Buy rating and $40 price target ArriVent is the leading oral EGFR TKI in front-line atypical EGFR mutated non-small cell lung cancer – a monotherapy regimen against EGFR exon 20 insertion and PACC mutations, the analyst tells investors in a research note. The firm expects pivotal Phase 3 data from EGFR ex20ins mutated lung cancer in the second half of 2025, and potential FDA approval within 12-15 months.